The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Non-Alcoholic Steatohepatitis Treatment Market Over The 2026–2030 Period?
The non-alcoholic steatohepatitis treatment market has experienced rapid expansion in its size over recent years. Projections indicate it will expand from $3.57 billion in 2025 to $4.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 39.6%. Factors contributing to its historical growth include the increasing prevalence of obesity, a rise in the incidence of type 2 diabetes, significant consumption of processed foods, insufficient awareness regarding liver health, and restricted treatment options available for early-stage nash.
The market for non-alcoholic steatohepatitis (NASH) treatment is anticipated to experience substantial growth over the next few years, projected to reach $18.97 billion by 2030 with a compound annual growth rate (CAGR) of 39.7%. This growth during the forecast period is fueled by advancements in precision medicine, the development of innovative NASH drugs, the adoption of digital health monitoring tools, government initiatives aimed at preventing liver disease, and increased investment in liver disease research. Key trends expected in this period include personalized lifestyle and diet management, progress in non-invasive diagnostic methods, programs to raise awareness about fatty liver disease, home-based liver health monitoring, and the creation of novel pharmacological agents.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
What Drivers Are Expected To Influence The Non-Alcoholic Steatohepatitis Treatment Market During The Forecast Period?
The non-alcoholic steatohepatitis treatment market is experiencing growth due to an increased prevalence of insulin resistance. Insulin resistance arises when muscle, fat, and liver cells do not respond effectively to insulin, thereby impeding the easy absorption of glucose from the blood and resulting in high blood sugar. This condition is linked to unhealthy lifestyles, excessive sugar consumption, and genetic factors. The utilization of non-alcoholic steatohepatitis treatment has risen because of the increased incidence of insulin resistance, often stemming from elevated diabetes and other liver-related issues. For example, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported that the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance significantly increased, moving from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2% respectively. Therefore, the expanding prevalence of insulin resistance, driven by various liver and diabetes diseases, is set to drive the non-alcoholic steatohepatitis treatment market.
How Is The Non-Alcoholic Steatohepatitis Treatment Market Segmented Across Key Categories?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Which Upcoming Trends Are Expected To Influence The Non-Alcoholic Steatohepatitis Treatment Market?
Major companies within the non-alcoholic steatohepatitis treatment market are creating innovative offerings, such as endogenous hormones, to attract wider customer bases, increase sales, and boost revenue. Endogenous hormones are substances naturally produced within the body by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is a distinct product due to its engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is being developed to address non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s uniqueness stems from its use of specialized glycoPEGylated technology, which ensures an extended half-life while maintaining its potency. This innovative approach enhances the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
Who Are The Dominant Players Shaping The Non-Alcoholic Steatohepatitis Treatment Market Landscape?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Read the full non-alcoholic steatohepatitis treatment market report here:
Which Region Is Forecast To Lead The Non-Alcoholic Steatohepatitis Treatment Market In Terms Of Market Size?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Alcoholic Steatohepatitis Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model